GGC oral supplement in people with mild cognitive impairment
Official title: Study For Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients
Run by University of Pittsburgh · NCT07583251 · Data updated 2026-11-12
This study tests whether taking Gamma Glutamylcysteine (GGC) at different daily doses is safe and tolerable for adults with mild cognitive impairment over three months.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 55 Years to 80 Years |
| Sex | All |
| Enrollment | 9 (estimated) |
| Sponsor | University of Pittsburgh Academic / other |
| Locations | 1 site (Pittsburgh, Pennsylvania) |
| Status | Recruiting |
| Started | August 4, 2026 |
| Main results expected | January 2027 |
| Study ends | February 2027 |
| Registry record updated | August 7, 2026 |
| Trial ID | NCT07583251 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 55–80 with a diagnosis of mild cognitive impairment and MoCA scores 18–25, able to read and write in English, without cancer or major psychiatric illness, not on antioxidant therapies or illicit drug use.
✕Probably not a fit
Participants with significant comorbidities, uncontrolled psychiatric conditions, active cancer history, or those already taking antioxidants or illegal drugs may not benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, open-label, dose-escalation Phase 1 trial in adults aged 55 to 80 with mild cognitive impairment. Participants will receive GGC oral supplementation at 400 mg, 800 mg, or 1200 mg per day for 3 months to assess safety and tolerability and to explore the maximum tolerated or recommended dose. The study aims to generate preliminary safety data to inform future larger trials. Outcomes will focus on adverse events, tolerability, and basic safety measures, with secondary observations on cognitive function and biomarkers related to oxidative stress. Result data will help determine feasibility of proceeding to controlled trials in this population.
Why it matters
Potential benefit: If successful, the study could identify a safe dose of GGC that might support brain antioxidant defenses in MCI and guide future research into disease-modifying strategies.
How similar studies have gone: Existing early-phase research in similar antioxidant strategies has shown safety and tolerability in related populations, but this exact GGC dosing in MCI is novel and preliminary.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Memory complaints; 2. MCI diagnosis 3. MoCA score between 18-25 4. Age 55 - 80 years old. 5. Ability to read and write in English Exclusion Criteria: 1. Subjects with a history of cancer; 2. Subjects with a history of schizophrenia, manic-depressive disorder 3. Subjects on antioxidant therapy (ashwagandha, gingko biloba, N-acetylcysteine or glutathione) 4. Subjects on illicit drug (cocaine, heroin, marijuana, or fentanyl) abuse/dependence;
Where it's running
-
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Pravat Mandal, PhD — University of Pittsburgh
- Study coordinator: Pravat Pravat K MANDAL
- Email: mandalpk@pitt.edu
- Phone: 4126999561
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Rural Veterans and Care Partners Walking Program
A virtual walking program is tested to see if it can help Veterans with mild cognitive impairment and their care partners in rural areas walk more each day.
-
China HEAD: a large community study on healthy aging and dementia
This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.
-
Aging Brain Health Initiative in Fujian
This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.
-
See if multimodal biomarkers can map changes from mild cognitive impairment to dementia
This observational study tests whether clinical, blood, and brain-imaging markers can tell apart stages of cognitive decline and predict progression from mild cognitive impairment to dementia in about 600 people.
-
LIFU to Help Sleep and Amyloid Reduction in Older Adults with Cognitive Impairment
A wearable ultrasound device (ATTN201) is being tested to see if it’s safe and easy to use for people 65 and older with mild cognitive impairment and amyloid buildup.
-
Digital STEADI: A home-based digital fall prevention program for older adults
A home-based digital program using AI-driven conversational agents tests if a guided fall-prevention exercise plan can reduce fall risk for older adults with mild cognitive impairment living independently.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.